| How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide. | |
| | |
MedLine Citation:
|
PMID: 16261414 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tamoxifen has been shown to reduce the incidence of invasive breast cancer in women at higher risk. Translating these research results to clinical practice is challenging. Our objective was to develop and evaluate a decision-making guide and process that can be used in clinical practice to inform eligible women of chemoprevention with tamoxifen. METHODS: A decision guide explaining the benefits and risks of tamoxifen was developed with input from health care professionals and two focus groups of women both with and without cancer. Following consent, 51 eligible women presenting to a multi-disciplinary diagnostic facility for breast problems were given the decision guide/questionnaire to read, fill out and return by mail. Women with further questions or wanting to take tamoxifen were encouraged to re-contact their physicians. RESULTS: Atypia was seen in 60% of subjects. Median 5-year Gail risk was 3.7 (range 1.7-9.4). Only 6 (11.8% 95% CI = 2.9, 20.6%) women reported they would like to take tamoxifen while 6 (11.8% 95% CI = 2.9, 20.6%) remained uncertain. CONCLUSION: We have developed a decision-making guide and process that is acceptable to providers and women to identify and inform women at higher risk of breast cancer with regard to chemoprevention with tamoxifen. Few women in this select group, when provided with a balanced decision guide, wished to pursue chemoprevention with tamoxifen. |
| | |
Authors:
|
Andrew McKay; Wanda Martin; Steven Latosinsky |
Related Documents
:
|
8542474 - Risk factors for wolfe's dysplasia of mammograms in postmenopausal turkish women. 8484374 - Breast cancer risk associated with abnormal cytology in nipple aspirates of breast flui... 21464984 - Body adiposity in later life and the incidence of dementia: the health in men study. 2982064 - Breast carcinoma at the extremes of age: a comparison of patients younger than 35 years... 17435444 - Work schedule during pregnancy and spontaneous abortion. 12237914 - Resources and use of the intensive care unit in patients who undergo surgery for ovaria... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: 94 ISSN: 0167-6806 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-11-01 Completed Date: 2007-09-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 153-9 Citation Subset: IM |
Affiliation:
|
Health Sciences Centre, University of Manitoba, Winnipeg, Canada. gooz99@mts.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Breast Neoplasms
/
epidemiology*,
etiology,
pathology,
prevention & control* Decision Support Techniques* Female Focus Groups Humans Manitoba / epidemiology Middle Aged Questionnaires Selective Estrogen Receptor Modulators / administration & dosage, therapeutic use* Tamoxifen / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Selective Estrogen Receptor Modulators; 10540-29-1/Tamoxifen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer.
Next Document: Anti-estrogenic effects of conjugated linoleic acid through modulation of estrogen receptor phosphor...